Search Results
Jul 23, 2026, 08:05 ET Accord BioPharma Announces Commercial Availability of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
discontinuation and treat appropriately.Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation: MVF have been reported following discontinuation of treatment with denosumab products. Patients at higher risk for MVF include those with risk factors for or a history of osteoporosis or
More news about: Accord BioPharma
Apr 29, 2026, 13:24 ET Industry Disrupter MyVirtualFleet Does It Again -- Launches TrackLink™, Free Broker Tracking That Saves $1,200-$5,000 a Month
curveCARLSBAD, Calif., April 29, 2026 /PRNewswire/ -- MyVirtualFleet (MVF), the freight dispatch platform that pioneered real-time broker email parsing for owner-operators and small carriers, today announced the general availability
More news about: MyVirtualFleet
Nov 20, 2025, 13:16 ET Accord BioPharma, Inc. Announces FDA Approval of Denosumab Biosimilars OSVYRTI® (denosumab-desu) and JUBEREQ® (denosumab-desu)
Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation: MVF have been reported following discontinuation of treatment with denosumab products. Patients at higher risk for MVF include those with risk factors for or a history of osteoporosis or
More news about: Accord BioPharma
Oct 30, 2025, 03:28 ET U.S. FDA grants interchangeability designation to Celltrion's denosumab biosimilars, STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo)
be considered, pending a benefit-risk assessment, on an individual basis. Multiple Vertebral Fractures (MVF) Following Discontinuation of Treatment: Increased risk post-discontinuation of denosumab; transition to alternative therapy if discontinuing STOBOCLO.
More news about: Celltrion
Oct 01, 2025, 07:30 ET Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
be monitored for signs and symptoms of hypercalcemia, and manage as clinically appropriate. Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation, when AUKELSO treatment is discontinued, evaluate the individual patient's risk for vertebral fractures.
More news about: Biocon Biologics
Sep 17, 2025, 07:32 ET Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars
Skeletons, patients should be monitored for signs and symptoms of hypercalcemia, and manage as clinically appropriate.Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation, when AUKELSO treatment is discontinued, evaluate the individual patient's risk for vertebral fractures.Embryo-Fetal
More news about: Biocon Biologics